Back to results
US 2025/0026828 A1Published application
Cd79a chimeric antigen receptors
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsKevin Friedman, Molly Reed Perkins
Life of this patent
Estimating the term…
Abstract
The invention provides improved compositions for adoptive cell therapies for cancers that express CD79A.
Claims21
-69. (canceled)
A chimeric antigen receptor (CAR) comprising:
- a) an extracellular domain that comprises an anti-CD79A antibody, or antigen binding fragment thereof, that binds a human CD79A polypeptide;
- wherein the anti-CD79A antibody, or antigen binding fragment thereof, comprises a variable light chain sequence comprising complementarity-determining region (CDR) sequences CDRL1-CDRL3 set forth in SEQ ID NOs:
- 1-3, and a variable heavy chain sequence comprising CDRH1-CDRH3 sequences set forth in SEQ ID NOs:
- 4-6;
- and wherein the variable heavy chain is positioned c-terminal to the variable light chain;
- b) a CD8α hinge region;
- c) a CD8α transmembrane domain;
- d) a 4-1BB (CD137) intracellular co-stimulatory signaling domain;
- and
- e) a CD3ζ primary signaling domain.
7 more elements
Dependencies are inferred from the claim text.